Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer

Next Previous
Trial Profile

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN-1059 (Primary) ; Pumitamig (Primary) ; Bevacizumab
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioNTech

Most Recent Events

  • 03 Nov 2025 According to the BioNTech Media Release, in August, the first patient was dosed in this Phase 1/2 clinical trial to evaluate BioNTech and Genmab's bispecific antibody candidate BNT314/GEN1059 in combination with pumitamig and chemotherapy in patients with advanced CRC.
  • 08 Aug 2025 Status changed from not yet recruiting to recruiting.
  • 04 Aug 2025 According to the BioNTech Media Release, this trial expected to start in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top